Diagnosis kit development

Through its DiagAlz project, IHD’s goal is the development of diagnostic kits for Alzheimer’s disease, for hospital use and pharmaceutical research.  DiagAlz project is a full part of worldwide research for a curative treatment of Alzheimer’s disease. Currently, there are more than 100 clinical trials being carried on for 70 different therapeutic targets. DiagAlz offers a test to detect and follow the Alzheimer’s pathology, as well as an optimizing method for present and future treatments. The company offers tools to the pharmaceutical industries involved in drug development and help for patient recruitment during clinical trials.

We are currently carrying clinical studies in order to complete the validation of two diagnostic tests. These studies should confirm our test efficiencies and verify their neutrality as compared to non Alzheimer’s dementia and other diseases.

Our goals are :
  • Partnership for new drug development,
  • Partnership for clinical trials and patient recruitment,
  • Primary diagnosis in clinical practice.